Phosphodiesterase 5 inhibitors and erectile dysfunction

Author： Sandner Peter Svenstrup Niels Tinel Hanna Haning Helmut Bischoff Erwin

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.18, Iss.1, 2008-01, pp. : 21-33

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction

Current Pharmaceutical Design, Vol. 12, Iss. 27, 2006-09 ,pp. : 3467-3484

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase-5 inhibitors for male erectile dysfunction

By Sui Zhihua

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 9, 2003-09 ,pp. : 1373-1388

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip Keel Christopher Klavens Meghan Hellstrom Wayne JG

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite

An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors

By Bruzziches Roberto

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1333-1344

Informa Healthcare

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3486-3495

Bentham Science Publishers

Access to resources Recommend Favorite